Therapeutic potential of an adenovirus expressing p73β, a p53 homologue, against human papilloma virus positive cervical cancer in vitro and in vivo

Cancer Biology and Therapy

Volumn 5, Issue 2, 2006, Pages 210-217

  Das, Sanjeev ^a   Somasundaram, Kumaravel ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Adenovirus; Cervical cancer; E6; Gene therapy; Human papilloma virus; p53; p73

Indexed keywords

BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN P53; PROTEIN P73; PROTEIN P73 BETA; UNCLASSIFIED DRUG;

ADENOVIRUS VECTOR; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE INDUCTION; GENE TARGETING; GENETIC TRANSFECTION; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; TISSUE CULTURE TECHNIQUE; TUMOR GROWTH; UTERINE CERVIX CANCER; VIRUS REPLICATION; WART VIRUS; XENOGRAFT;

EID: 33644645005     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.2.2402     Document Type: Article

References (64)

1. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Eng J Med 1999; 340:1137-43.
2. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Eng J Med 1999; 340:1144-53.
3. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, Walker JL, Gersell D. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Eng J Med 1999; 340:1154-61.
4. Rose PG, Eifel PJ. Principles and Practice of Oncology, eds. DeVita V, Hellman S, Rosenberg S, (Lippincott-Raven: Philadelphia, PA), 2000; 14:1-14:10.
5. Brinton LA. in The epidemiology of human papillomavirus and cervical cancer, eds. Munoz, N., Bosch, F., Shah, K.V., & Meheus, A. (Oxford University Press, Oxford), 1992; 3-23.
6. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001; 51:15-36.
7. Syrjanen KJ, Epidemiology of human papillomavirus (HPV) infections and their associations with genital squamous cell cancer. APMIS 1989; 97:957-70.
8. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kumaran R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796-802.
9. Lungu O, Sun XW, Wright-TC J, Ferenczy A, Richart RM, Silverstein S. A polymerase chain reaction-enzyme-linked immunosorbent assay method for detecting human papillomavirus in cervical carcinomas and high-grade cervical cancer precursors. Obstet Gynecol 1995; 85:337-42.
10. Qu W, Jiang G, Cruz Y, Chang CJ, Ho GY, Klein RS, Burk RD. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 1997; 35:1304-10.
11. Park JS, Hwang ES, Park SN, Ahn HK, Um SJ, Kim CJ, Namkoong SE. Physical status and expression of HPV genes in cervical cancers. Gynecol Oncol 1997, 65:121-9.
12. Choo CK, Ling MT, Chan KW, Tsao SW, Zheng Z, Zhang D, Chan LC, Wong YC. Immortalization of human prostate epithelial cells by HPV 16 E6/E7 open reading frames. Prostate 1999; 40:150-8.
13. Kaur P, McDougall JK. HPV-18 immortalization of human keratinocytes. Virology 1989; 173:302-10.
14. Pecoraro G, Morgan D, Defendi V. Differential effects of human papillomavirus type 6, 16, and 18 DNAs on immortalization and transformation of human cervical epithelial cells. Proc Natl Acad Sci USA 1989; 86; 563-7.
15. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129-36.
16. Scheffner M, Huibregtse JM, Vierstra RD, Howley, PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75:495-505.
17. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBOJ 1989; 8:4099-105.
18. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996; 56:4620-4.
19. Heck DV, Yee CL, Howley PM, Munger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci USA 1992; 89:4442-6.
20. Schmitt A, Harry JB, Rapp B, Wettstein FO, Iftner T. Comparison of the properties of the E6 and E7 genes of low- and high-risk cutaneous papillomaviruses reveals strongly transforming and high Rb-binding activity for the E7 protein of the low-risk human papillomavirus type 1. J Virol 1994; 68:7051-9.
21. Yoshinouchi M, Yamada T, Kizaki M, Fen J, Koseki T, Ikeda Y, Nishihara T, Yamato K. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Therapy 2003; 8:763-8.
22. Choo CK, Ling MT, Suen CK, Chan KW, Kwong YL. Retrovirus-mediated delivery of HPV16 E7 antisense RNA inhibited tumorigenicity of CaSki cells. Gynecol Oncol 2000; 78:293-301.
23. Cho CW, Poo H, Cho YS, Cho MC, Lee KA, Lee SJ, Park SN, Kim IK, Jung YK, Choe YK, Yeom YI, Choe IS, Yoon do Y. HPV E6 antisense induces apoptosis in CaSki cells via suppression of E6 splicing. Exp Mol Med 2002; 34:159-66.
24. Hamada K, Sakaue M, Alemany R, Zhang WW, Horio Y, Roth JA, Mitchell MF. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Gynecol Oncol 1996; 63:219-27.
25. Nakamura M, Kyo S, Kanaya T, Yatabe N, Maida Y, Tanaka M, Ishida Y, Jujii C, Kondo T, Inoue M, Mukaida N. hTERT-promoter-based tumor-specific expression of MCP-1 effectively sensitizes cervical cancer cells to a low dose of cisplatin. Cancer Gene Ther 2004; 11:1-7.
26. Huh WK, Gomez-Navarro J, Arafat WO, Xiang J, Mahasreshti PJ, Alvarez RD, Barnes MN, Curiel DT. Bax-induced apoptosis as a novel gene therapy approach for carcinoma of the cervix. Gynecol Oncol 2001; 83:370-7.
27. Tsao YP, Huang SJ, Chang JL, Hsieh JT, Pong RC, Chen, SL. Adenovirus-mediated p21((WAF1/SDII/CIP1)) gene transfer induces apoptosis of human cervical cancer cell lines. J Virol 1999; 73:4983-90.
28. Ip SM, Huang TG, Yeung WS, Ngan HY. pRb-expressing adenovirus Ad5-Rb attenuates the p53-induced apoptosis in cervical cancer cell lines. Eur J Cancer 2001, 37:2475-83.
29. Huh JJ, Wolf JK, Fightmaster DL, Lotan R, Follen M. Transduction of adenovirus-mediated wild-type p53 after radiotherapy in human cervical cancer cells. Gynecol Oncol 2003; 89:243-50.
30. Hamada K, Alemany R, Zhang WW, Hittelman WN, Lotan R, Roth JA, Mitchell MF. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res 1996; 56:3047-54.
31. Prabhu NS, Blagosklonny M, Zeng YX, Wu GS, Waldman T, El-Deiry WS. Suppression of cancer cell growth by adenovirus expressing p21(WAF1/CIP1) deficient in PCNA interaction. Clin Cancer Res 1996; 2:1221-9.
32. Tsang NM, Nagasawa H, Li C, Little JB. Abrogation of p53 function by transfection of HPV16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. Oncogene 1995; 10:2403-8.
33. Jost CA, Marin MC, Kaelin WG. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 1997; 389:191-4.
34. Kaghad M, Bonnet H, Yang A, Creancier L, Jean-Christophe B, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90:809-19.
35. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404:99-103.
36. Takada N, Ozaki T, Ichimiya S, Todo S, Nakagawara A. Identification of a transactivation activity in the COOH-terminal region of p73 which is impaired in the naturally occurring mutants found in human neuroblastomas. Cancer Res 1999; 59:2810-4.
37. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, Baylin SB, Herman JG. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res 1999; 59:3352-6.
38. Kawano S, Miller CW, Gombart AF, Bartram CR, Matsuo Y, Asou H, Sakashita A, Said J, Tatsumi E, Koeffler HP. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 1999; 94:1113-20.
39. Irwin MS, Kaelin, WG. Role of the newer p53 family proteins in malignancy. Apoptosis 2001; 6:17-29.
40. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X, Kaelin WG Jr, Oren M, Chen J, Lu H. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 1999; 19:3257-66.
41. Balint E, Bates W, Vousden K. Mdm2 binds p73 alpha without targeting degradation. Oncogene 1999; 18:3923-9.
42. Prabhu NS, Somasundaram K, Satyamoorthy K, Herlyn M, El-Deiry WS. p73beta, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Int J Oncol 1998; 13:5-9.
43. Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D, Kaelin WG. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol 1998; 18:6316-6324.
44. Dobbelstein M, Roth J. The large T antigen of simian virus 40 binds and inactivates p53 but not p73. J Gen Virol 1998; 79:3079-83.
45. Das S, El-Deiry WS, Somasundaram K. Efficient growth inhibition of HPV 16 E6-expressing cells by an adenovirus-expressing p53 homologue p73beta. Oncogene 2003; 22:8394-402.
46. Wu GS, El-Deiry WS. Clin Cancer Res 1996; 4:623-33.
47. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. Cell 1993; 75:817-25.
48. Somasundaram K, El-Deiry WS. Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene 1997; 14:1047-57.
49. Blagosklonny M, El-Deiry WS. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int J Cancer 1996; 67:386-92.
50. Joseph J, Mudduluru G, Antony S, Vashistha S, Ajitkumar P, Somasundaram K. Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene 2004; 23:6304-15.
51. Das S, El-Deiry WS, Somasundaram K. Regulation of the p53 homolog p73 by adenoviral oncogene E1A. J Biol Chem 2003; 278:18313-20.
52. Yadav VK, Sudhagar RR, Medhamurthy R. Apoptosis during spontaneous and prostaglandin F(2alpha)-induced luteal regression in the buffalo cow (Bubalus bubalis): involvement of mitogen-activated protein kinases. Biol Reprod 2002; 67:752-9.
53. Lebedeva IV, Su Z, Sarkar D, Fisher PB. Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. Semin Cancer Biol 2003; 13:169-78.
54. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362:857-60.
55. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-9.
56. Kubbutat MGH, Jones SN, Vousden K. Regulation of p53 stability by Mdm2 Nature 1997; 387:299-303.
57. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998; 5:8292-7.
58. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17:5001-14.
59. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725-34.
60. Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Rabbani F, Meyer F, Fradet Y, Cordon-Cardo C. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol 1999; 155:105-13.
61. Yatabe N, Kyo S, Kondo S, Kanaya T, Wang Z, Maida Y, Takakura M, Nakamura M, Tanaka M, Inoue M. 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther 2002; 9:624-30.
62. Das S, Nama S, Antony S, Somasundaram K. p73 expressing recombinant adenovirus: a potential anti-cancer agent. Cancer Gene Ther 2005; 12:417-26.
63. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG. Chemosensitivity linked to p73 function. Cancer Cell 2003; 3:403-10.
64. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416:560-4.